Clinical trials: Tamsulosin
Prostatic Hyperplasia
A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.
Dutasteride and tamsulosin are to treat benign prostatic hyperplasia. Studies show that when given together, there is more improvement in symptoms than either drug alone.
- Trial name
- NCT00609596
- Testing
- GI198745
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
To evaluate the efficacy and safety of solifenacin succinate as add-on therapy for overactive bladder (OAB) symptoms in men who have been treated for benign prostatic hyperplasia (BPH) with tamsulosin hydrochloride for at least 6…
- Conditions
- Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy, Overactive Bladder
- Trial name
- NCT00771394
- Testing
- Tamsulosin hydrochloride, Solifenacin succinate
- Where
- 8 sites in Japan
- Volunteers
- 638 people
- Sponsor
- Astellas Pharma Inc
Prostatic Hyperplasia
Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement
Study FDC114615 is a two year, multi-centre, randomised, open-label trial to assess the efficacy of Dutasteride plus tamsulosin when compared to the standard practice of watchful waiting, with a defined escalation to tamsulosin…
- Trial name
- CONDUCT (NCT01294592)
- Testing
- Dutasteride plus tamsulosin, tamsulosin
- Where
- 80 sites in France, Germany and 6 more
- Volunteers
- 742 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)
The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia).
- Trial name
- NCT02245503
- Testing
- Tamsulosin
- Volunteers
- 7,391 people
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.
Two tamsulosin HClformulations will be tested in fed state
- Trial name
- NCT02417844
- Testing
- tamsulosin (Astellas), Tamsulosin HCL
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with…
- Trial name
- NCT00090103
- Testing
- dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years
- Where
- 503 sites in United States, Argentina and 34 more
- Volunteers
- 4,844 people
- Sponsor
- GlaxoSmithKline
Prostate Hyperplasia
FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)
To establish whether the administration of FLOMAX® improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention and to determine whether spontaneous voiding is maintained over the course of…
- Trial name
- NCT02244294
- Testing
- FLOMAX® capsules
- Volunteers
- 176 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)
Benign prostatic hyperplasia (BPH), also known as an enlarged prostate, happens more often in men as they age. This condition causes a sudden need to pass urine, which is hard to control.
- Trial name
- NCT07619105
- Testing
- Vesomni
- Volunteers
- 600 people
- Sponsor
- Astellas Pharma Korea, Inc.
Healthy
Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers
Study to investigate the effect of CYP2D6 inhibition by paroxetine on the single oral dose pharmacokinetics of tamsulosin and to investigate the effect on safety and tolerability
- Trial name
- NCT02264184
- Testing
- Tamsulosin, Paroxetine
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia (BPH)
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Inflammation is reported as one of the most recent hypotheses to explain BPH. Recent published works pointed out that urine and serum markers could be used for detection of prostatic inflammation.
- Trial name
- PERMIN (NCT01604811)
- Testing
- Permixon® 160 mg, Tamsulosine Arrow LP
- Where
- 32 sites in France, Italy and 2 more
- Volunteers
- 206 people
- Sponsor
- Pierre Fabre Medicament
Healthy
A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers
Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers
- Trial name
- NCT02072213
- Testing
- GL2702 GLARS-NF1, Omix Ocas
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Benign Prostatic Hyperplasia
Study to Compare the Safety and Pharmacokinetics of CKD-397
The purpose of this study is to compare the safety and pharmacokinetics profiles of CKD-397 in healthy male volunteers.
- Trial name
- CKD-397 (NCT02645890)
- Testing
- CKD-397, TD+TM
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
CKD-397 Drug-drug Interaction Study (A)
The purpose of this study is to investigate to effect of tamsulosin on the pharmacokinetic properties of tadalafil
- Trial name
- CKD-397DDI(A) (NCT02247518)
- Testing
- Cialis Tab. 5mg, Harnal-D Cap. 0.2mg
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Lower Urinary Tract Symptoms, Overactive Bladder
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
The objective of this study is to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms (LUTS) including overactive bladder…
- Conditions
- Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT02715024
- Testing
- Tamsulosin, Solifenacin
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Taiwan, Inc.
Erectile Dysfunction
Phase I Study to Investigate the Drug Interaction After Oral Administration of Tamsulosin and SK3530
To assess the pharamcodynamic effects of coadministrated SK3530(PDE5 inhibitor) and tamsulosin, phase I study in healthy volunteers was designed.
- Trial name
- NCT00489606
- Testing
- SK3530
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Healthy
Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects
The objective of this study is to determine the bioequivalence of two batches of Flomax® 0.4 mg capsules in healthy male subjects.
- Trial name
- NCT02266511
- Testing
- Flomax®, Norman II facility, Flomax®, Nishine facility
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Urinary Incontinence
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge…
- Trial name
- NCT00147654
- Testing
- Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
- Where
- 95 sites in United States
- Volunteers
- 830 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Urological Manifestations
Actual Use Study of Tamsulosin in Men
An actual use study to assess how men who respond to advertisements about urinary symptoms use tamsulosin in a simulated Over the Counter (OTC) setting including following "stop use and ask a doctor if" and "ask a doctor before…
- Trial name
- NCT02573311
- Testing
- tamsulosin hydrochloride
- Where
- 40 sites in United States
- Volunteers
- 1,117 people
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Bioequivalence - Duodart Against Avodart & Omnic
Open-label, randomized, single dose, two-treatment, two-way crossover study
- Trial name
- NCT01657851
- Testing
- dutasteride/tamsulosin, dutasteride, tamsulosin
- Where
- Russia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms
Study to evaluate the efficacy of tamsulosin on storage symptoms and detrusor motor activity in patients with LUTS suggestive of BPH and relevant storage symptoms
- Trial name
- NCT02245490
- Testing
- Tamsulosin HCl controlled release capsules
- Volunteers
- 153 people
- Sponsor
- Boehringer Ingelheim